Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography
Sponsor: Cairo University
Summary
This randomized, double-blind, placebo-controlled, will evaluate whether oral hyoscine butylbromide or topical eutectic lidocaine-prilocaine (EMLA) spray reduces pain during hysterosalpingography (HSG) compared with placebo
Official title: Safety and Efficacy of Oral Hyoscine Butylbromide Versus Topical EMLA Spray in Reducing Pain During Hysterosalpingography: A Randomized Double-Blind Placebo-Controlled Trial
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2025-10-03
Completion Date
2026-03-30
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
Oral Hyoscine butylbromide and Placebo Spray
Hyoscine butylbromide 20 mg oral tablet, single dose 30 min before HSG PLUS placebo cervical spray
Topical EMLA Spray and Placebo Oral Tablet
EMLA spray (lidocaine 2.5% + prilocaine 2.5%), 3 sprays to ectocervix/external os, 10 min before HSG plus placebo oral tablet
Double Placebo
oral placebo tablet plus placebo cervical spray
Locations (1)
Al Gezeera Hospital
Giza, Egypt